MY142283A - Diagnosis and treatment of cancers and other conditions - Google Patents
Diagnosis and treatment of cancers and other conditionsInfo
- Publication number
- MY142283A MY142283A MYPI20023310A MYPI20023310A MY142283A MY 142283 A MY142283 A MY 142283A MY PI20023310 A MYPI20023310 A MY PI20023310A MY PI20023310 A MYPI20023310 A MY PI20023310A MY 142283 A MY142283 A MY 142283A
- Authority
- MY
- Malaysia
- Prior art keywords
- probe
- receptors
- functional
- treatment
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
THE INVENTION CONCERNS A WIDE RANGE OF DISEASES AND CONDITIONS, INCLUDING CANCERS. THE INVENTION PROVIDES A PROBE FOR DETECTION OF SUCH A DISEASE OR CONDITION. THE PROBE IS ABLE TO DISTINGUISH BETWEEN FUNCTIONAL P2X7 RECEPTORS AND NON-FUNCTIONAL P2X7 RECEPTORS. THE PROBE CAN DO THIS IN VARIOUS WAYS, ONE OF WHICH IS DETECTING CHANGE IN RELATION TO BINDING OF ADENOSINE TRIPHOSPHATE (ATP) TO THE RECEPTORS. THE INVENTION ALSO PROVIDES A METHOD OF DETECTING THE DISEASE OR CONDITION, USING THE PROBE. THE INVENTION EXTENDS TO TREATMENT OF THE DISEASE OR CONDITION, USING AN ANTIBODY, OR AN EPITOPE CAPABLE OF GENERATING THE ANTIBODY, WHICH CAN DISTINGUISH BETWEEN FUNCTIONAL AND NON-FUNCTIONAL P2X7 RECEPTORS AND BIND TO THE NON-FUNCTIONAL RECEPTORS. METHODS OF TREATMENT, PHARMACEUTICAL COMPOSITIONS AND USE OF THE PROBE AND ANTIBODY ARE ALSO INCLUDED.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPR7431A AUPR743101A0 (en) | 2001-09-03 | 2001-09-03 | A cancer therapeutic |
| AUPR7430A AUPR743001A0 (en) | 2001-09-03 | 2001-09-03 | Diagnosis and treatment of irritable bowel syndrome |
| PCT/AU2002/000061 WO2002057306A1 (en) | 2001-01-17 | 2002-01-17 | Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY142283A true MY142283A (en) | 2010-11-15 |
Family
ID=41706691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI20023310A MY142283A (en) | 2001-09-03 | 2002-09-04 | Diagnosis and treatment of cancers and other conditions |
Country Status (9)
| Country | Link |
|---|---|
| JP (1) | JP4467973B2 (en) |
| CN (2) | CN101445555B (en) |
| AU (1) | AU2002322192B2 (en) |
| CA (1) | CA2459348C (en) |
| MY (1) | MY142283A (en) |
| NZ (2) | NZ549019A (en) |
| TW (1) | TWI329648B (en) |
| WO (1) | WO2003020762A1 (en) |
| ZA (1) | ZA200402630B (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60230482D1 (en) | 2001-01-17 | 2009-02-05 | Intreat Pty Ltd | ANTIBODIES TO NON-FUNCTIONAL P 2X7 RECEPTORS, DIAGNOSIS AND TREATMENT OF CANCER AND OTHER SUFFERING |
| JP4746987B2 (en) * | 2002-12-05 | 2011-08-10 | ケーエルエー−テンカー コーポレイション | Apparatus and method for detecting overlay error using scatterometry |
| EP1615991A4 (en) | 2003-04-03 | 2007-12-19 | Bristol Myers Squibb Co | Polynucleotide encoding a novel human p2x7 splice variant, hbmyp2x7v |
| US8124730B1 (en) | 2004-04-02 | 2012-02-28 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v |
| US7767789B2 (en) * | 2005-06-02 | 2010-08-03 | University Hopitals of Cleveland | Truncated proteins as cancer markers |
| US20100036101A1 (en) * | 2006-10-10 | 2010-02-11 | Angus Gidley-Baird | Antibodies against non functional p2x7 receptor |
| JP2010505426A (en) * | 2006-10-10 | 2010-02-25 | バイオスセプター インターナショナル リミテッド | Hybridoma producing antibody against non-functional P2X7 receptor |
| AU2013238152B2 (en) * | 2007-09-14 | 2015-09-24 | Biosceptre International Limited | Purinergic (P2X) receptors in extra-cellular body fluid |
| WO2009033234A1 (en) | 2007-09-14 | 2009-03-19 | Biosceptre International Limited | Purinergic (p2x) receptors in extra-cellular body fluid |
| NZ583894A (en) * | 2007-09-14 | 2013-01-25 | Biosceptre Int Ltd | Antibodies that bind to a non atp binding p2x7 receptor |
| EP2318438B1 (en) * | 2008-07-04 | 2016-11-02 | Biosceptre (Aust) Pty Ltd | Anti-p2x7 peptiden und epitopen |
| CN101469352B (en) * | 2008-08-29 | 2011-12-21 | 苏州福英基因科技有限公司 | In situ hybridization detection kit for early uterocarcinoma |
| ES2904911T3 (en) * | 2009-08-20 | 2022-04-06 | Biosceptre Aust Pty Ltd | Anti-P2X7 receptor antibodies and fragments thereof |
| AU2010336032C1 (en) * | 2009-12-24 | 2016-04-21 | Biosceptre International Limited | Antibodies to non-functional oligomeric P2X7 receptors |
| EP2613808B1 (en) * | 2010-09-10 | 2017-11-08 | Biosceptre (Aust) Pty Ltd | Companion animal cancer treatments with an anti p2x7 antibody |
| US9566318B2 (en) * | 2011-07-01 | 2017-02-14 | Biosceptre (Aust) Pty Ltd | Combination therapy |
| EP2990800A1 (en) * | 2014-08-29 | 2016-03-02 | Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol | Neprilysin as heartfailure (HF) prognostic marker |
| US20190365805A1 (en) | 2015-09-11 | 2019-12-05 | Carina Biotech Pty Ltd | Chimeric antigen receptors and uses thereof |
| AU2017346936B2 (en) | 2016-10-21 | 2022-10-06 | Biosceptre (Aust) Pty Ltd | Cytotoxic particles |
| CN110054691B (en) * | 2019-05-09 | 2021-09-07 | 潍坊医学院 | Hybridoma cell line of anti-human P2RX7 monoclonal antibody |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6133434A (en) * | 1997-04-28 | 2000-10-17 | Glaxo Group Limited | Purinergic receptor |
| DE60230482D1 (en) * | 2001-01-17 | 2009-02-05 | Intreat Pty Ltd | ANTIBODIES TO NON-FUNCTIONAL P 2X7 RECEPTORS, DIAGNOSIS AND TREATMENT OF CANCER AND OTHER SUFFERING |
-
2002
- 2002-09-03 NZ NZ549019A patent/NZ549019A/en not_active IP Right Cessation
- 2002-09-03 JP JP2003525032A patent/JP4467973B2/en not_active Expired - Lifetime
- 2002-09-03 CN CN2008102142942A patent/CN101445555B/en not_active Expired - Lifetime
- 2002-09-03 TW TW091120122A patent/TWI329648B/en not_active IP Right Cessation
- 2002-09-03 WO PCT/AU2002/001204 patent/WO2003020762A1/en active Application Filing
- 2002-09-03 NZ NZ565994A patent/NZ565994A/en not_active IP Right Cessation
- 2002-09-03 CN CNB028214331A patent/CN100497386C/en not_active Expired - Lifetime
- 2002-09-03 AU AU2002322192A patent/AU2002322192B2/en not_active Expired
- 2002-09-03 CA CA2459348A patent/CA2459348C/en not_active Expired - Lifetime
- 2002-09-04 MY MYPI20023310A patent/MY142283A/en unknown
-
2004
- 2004-04-02 ZA ZA2004/02630A patent/ZA200402630B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP4467973B2 (en) | 2010-05-26 |
| CA2459348A1 (en) | 2003-03-13 |
| TWI329648B (en) | 2010-09-01 |
| CN101445555B (en) | 2013-07-03 |
| CN100497386C (en) | 2009-06-10 |
| NZ549019A (en) | 2008-05-30 |
| WO2003020762A1 (en) | 2003-03-13 |
| NZ565994A (en) | 2010-02-26 |
| JP2005513416A (en) | 2005-05-12 |
| AU2002322192B2 (en) | 2008-05-01 |
| CA2459348C (en) | 2013-06-18 |
| CN101445555A (en) | 2009-06-03 |
| CN1625565A (en) | 2005-06-08 |
| ZA200402630B (en) | 2005-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY158262A (en) | Diagnosis and treatments of cancers and other conditions | |
| MY142283A (en) | Diagnosis and treatment of cancers and other conditions | |
| KR100711046B1 (en) | Use of nicotinamide n-methyltransferase as a marker for colorectal cancer | |
| ATE461449T1 (en) | METHOD FOR DETECTING MEDICALLY RELEVANT CONDITIONS IN DISSOLVED LBC SAMPLES | |
| ATE337011T1 (en) | MODIFIED PSMA LIGANDS AND USE THEREOF | |
| ATE438853T1 (en) | DIAGNOSTIC TEST APPARATUS | |
| HK1082200A1 (en) | Compositions and methods for the therapy of inflammatory bowel disease | |
| EP2021794B8 (en) | Use of protein s100a 12 as a marker for colorectal cancer | |
| HUP0303888A2 (en) | Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer | |
| DK1692181T3 (en) | Leptin antagonist and method for quantitative measurement of leptin | |
| WO2021038112A3 (en) | Apparatus and method for determination of banned substances | |
| WO2004022006A3 (en) | Methods of diagnosing cervical cancer | |
| WO2008060376A3 (en) | Algorithims for multivariant models to combine a panel of biomarkers for assessing the risk of developing ovarian cancer | |
| DE602005013430D1 (en) | USING ASC AS A MARKER FOR COLORECTAL CARCINOMAS | |
| WO2004074325A3 (en) | Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers | |
| DE50011181D1 (en) | PROOF OF THE PYRUVATE KINASE ISOENZYME IN THE CHAIR | |
| DE602004017317D1 (en) | USE OF THE PROTEINS PROTEINASE 3 (PRN3) AND LEUKOCYTES ELASTATES INHIBITOR (ILEU) AS A MARKER FOR COLORECTAL CARCINOMAS | |
| MXPA04004018A (en) | Methods of screening for toxicity of test compounds. | |
| NO20022441L (en) | Methods for Treating Lupus Based on Antibody Affinity and Screening Methods, and Preparations for Use thereof | |
| WO2003104761A3 (en) | Measurement of melanocortin peptides and uses thereof | |
| BR0308117A (en) | Avidin dimers effective in increasing radioactive biotin concentration in pre-directed radioimmunotherapy | |
| EP0563244A4 (en) | Human phospholipase activating protein and methods for diagnosis of rheumatoid arthritis | |
| DE60127935D1 (en) | METHOD FOR DIAGNOSING THE EFFECTIVENESS OF XENOTYPIC ANTIBODY THERAPY | |
| DE50006083D1 (en) | LABORATORY EXAMINATION OF A BODY LIQUID OR TISSUE SAMPLE | |
| PT1297342E (en) | METHOD OF DIAGNOSIS FOR ALZHEIMER'S DISEASE BASED ON HOLO-TRANSCOBALAMIN II |